Nakai K, Nakai K, Itoh C, Kikuchi M, Nakamura S, Kamata J, Hiramori K, Yumura W, Horita S, Sugino N
Department of Clinical Pathology, Iwate Medical University, Morioka.
Rinsho Byori. 1992 May;40(5):529-34.
In this study, we measured cMLC1 concentration in serum and urine from patients with acute myocardial infarction (AMI), chronic renal failure (CRF), and various grades of renal dysfunction (RD) in comparison with normal controls, by using enzyme immunoassay (EIA) with monoclonal antibody, and attempted to elucidate the mechanism of increased serum level of cMLC1 in patients with renal failure. The serum level of cMLC1 of CRF patients under maintenance hemodialysis (HD) was 20.3 +/- 19.6 ng/ml, markedly higher than normal controls (0.54 +/- 0.55 ng/ml). The patients with RD and CRF under conservative therapy had higher serum cMLC1 level than normal controls especially in advanced CRF, while each value not correlating with their creatine clearance (Ccr). cMLC1 in urine was detectable in only two cases with AMI accompanied with CRF or RD. In addition, immunohistological studies of renal biopsy specimens from RD patients did not show cMLC1 deposits in glomerulus. These results suggest that cMLC1 is assumably filtered through the glomerulus, and then absorbed in the renal tubule.
在本研究中，我们使用单克隆抗体酶免疫测定法（EIA），测定了急性心肌梗死（AMI）、慢性肾衰竭（CRF）及不同程度肾功能不全（RD）患者血清和尿液中的cMLC1浓度，并与正常对照组进行比较，试图阐明肾衰竭患者血清中cMLC1水平升高的机制。维持性血液透析（HD）的CRF患者血清cMLC1水平为20.3±19.6 ng/ml，显著高于正常对照组（0.54±0.55 ng/ml）。保守治疗的RD和CRF患者血清cMLC1水平高于正常对照组，尤其是晚期CRF患者，而各值与肌酐清除率（Ccr）均无相关性。仅在2例伴有CRF或RD的AMI患者尿液中检测到cMLC1。此外，对RD患者肾活检标本的免疫组织学研究未显示肾小球中有cMLC1沉积。这些结果表明，cMLC1可能经肾小球滤过，然后在肾小管被重吸收。
